Cystic Fibrosis Transmembrane Conductance Regulator
"Cystic Fibrosis Transmembrane Conductance Regulator" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chloride channel that regulates secretion in many exocrine tissues. Abnormalities in the CFTR gene have been shown to cause cystic fibrosis. (Hum Genet 1994;93(4):364-8)
MeSH Number(s)
D12.776.157.530.400.175.125
D12.776.543.550.425.175.125
D12.776.543.585.400.175.125
Below are MeSH descriptors whose meaning is more general than "Cystic Fibrosis Transmembrane Conductance Regulator".
Below are MeSH descriptors whose meaning is more specific than "Cystic Fibrosis Transmembrane Conductance Regulator".
This graph shows the total number of publications written about "Cystic Fibrosis Transmembrane Conductance Regulator" by people in Harvard Catalyst Profiles by year, and whether "Cystic Fibrosis Transmembrane Conductance Regulator" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 0 | 11 | 11 |
| 1992 | 0 | 10 | 10 |
| 1993 | 0 | 6 | 6 |
| 1994 | 0 | 6 | 6 |
| 1995 | 2 | 2 | 4 |
| 1996 | 7 | 0 | 7 |
| 1997 | 5 | 2 | 7 |
| 1998 | 7 | 1 | 8 |
| 1999 | 6 | 0 | 6 |
| 2000 | 6 | 4 | 10 |
| 2001 | 7 | 3 | 10 |
| 2002 | 7 | 2 | 9 |
| 2003 | 4 | 4 | 8 |
| 2004 | 9 | 4 | 13 |
| 2005 | 5 | 5 | 10 |
| 2006 | 5 | 1 | 6 |
| 2007 | 7 | 4 | 11 |
| 2008 | 7 | 3 | 10 |
| 2009 | 11 | 7 | 18 |
| 2010 | 5 | 8 | 13 |
| 2011 | 8 | 3 | 11 |
| 2012 | 5 | 3 | 8 |
| 2013 | 4 | 3 | 7 |
| 2014 | 6 | 2 | 8 |
| 2015 | 6 | 7 | 13 |
| 2016 | 9 | 6 | 15 |
| 2017 | 11 | 4 | 15 |
| 2018 | 7 | 2 | 9 |
| 2019 | 10 | 5 | 15 |
| 2020 | 5 | 2 | 7 |
| 2021 | 1 | 1 | 2 |
Below are the most recent publications written about "Cystic Fibrosis Transmembrane Conductance Regulator" by people in Profiles.
-
Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial. Am J Respir Crit Care Med. 2021 02 01; 203(3):381-385.
-
A dyadic approach to the delineation of diagnostic entities in clinical genomics. Am J Hum Genet. 2021 01 07; 108(1):8-15.
-
Ivacaftor Reverses Airway Mucus Abnormalities in a Rat Model Harboring a Humanized G551D-CFTR. Am J Respir Crit Care Med. 2020 11 01; 202(9):1271-1282.
-
Extracellular cyclic dinucleotides induce polarized responses in barrier epithelial cells by adenosine signaling. Proc Natl Acad Sci U S A. 2020 11 03; 117(44):27502-27508.
-
Survey of patients with cystic fibrosis and caregivers decisions regarding CFTR modulators. Pediatr Pulmonol. 2020 11; 55(11):2983-2989.
-
Drosophila as a model for studying cystic fibrosis pathophysiology of the gastrointestinal system. Proc Natl Acad Sci U S A. 2020 05 12; 117(19):10357-10367.
-
Correcting CFTR: New Gene Editing Strategies for Rescuing CFTR Function Ex Vivo. Cell Stem Cell. 2020 04 02; 26(4):476-478.
-
A human ciliopathy reveals essential functions for NEK10 in airway mucociliary clearance. Nat Med. 2020 02; 26(2):244-251.
-
Increased expression of anion transporter SLC26A9 delays diabetes onset in cystic fibrosis. J Clin Invest. 2020 01 02; 130(1):272-286.
-
A Novel AAV-mediated Gene Delivery System Corrects CFTR Function in Pigs. Am J Respir Cell Mol Biol. 2019 12; 61(6):747-754.